vs
Side-by-side financial comparison of Amneal Pharmaceuticals, Inc. (AMRX) and CURTISS WRIGHT CORP (CW). Click either name above to swap in a different company.
CURTISS WRIGHT CORP is the larger business by last-quarter revenue ($947.0M vs $814.3M, roughly 1.2× Amneal Pharmaceuticals, Inc.). CURTISS WRIGHT CORP runs the higher net margin — 14.5% vs 4.3%, a 10.2% gap on every dollar of revenue. On growth, CURTISS WRIGHT CORP posted the faster year-over-year revenue change (14.9% vs 11.5%). CURTISS WRIGHT CORP produced more free cash flow last quarter ($315.1M vs $108.5M). Over the past eight quarters, CURTISS WRIGHT CORP's revenue compounded faster (15.2% CAGR vs 11.1%).
Amneal Pharmaceuticals, Inc. is an American publicly traded pharmaceutical company that develops, manufactures and distributes generics and specialty pharmaceutical products. The company is headquartered in Bridgewater, New Jersey, and is one of the largest manufacturers of generic drugs in the United States.
The Curtiss-Wright Corporation is an American manufacturer and services provider headquartered in Davidson, North Carolina, with factories and operations in and outside the United States. Created in 1929 from the consolidation of Curtiss, Wright, and various supplier companies, the company was immediately the country's largest aviation firm and built more than 142,000 aircraft engines for the U.S. military during World War II.
AMRX vs CW — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $814.3M | $947.0M |
| Net Profit | $35.1M | $137.0M |
| Gross Margin | 36.5% | 37.5% |
| Operating Margin | 13.8% | 19.2% |
| Net Margin | 4.3% | 14.5% |
| Revenue YoY | 11.5% | 14.9% |
| Net Profit YoY | 212.9% | 16.2% |
| EPS (diluted) | $0.10 | $3.69 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $814.3M | $947.0M | ||
| Q3 25 | $784.5M | $869.2M | ||
| Q2 25 | $724.5M | $876.6M | ||
| Q1 25 | $695.4M | $805.6M | ||
| Q4 24 | $730.5M | $824.3M | ||
| Q3 24 | $702.5M | $798.9M | ||
| Q2 24 | $701.8M | $784.8M | ||
| Q1 24 | $659.2M | $713.2M |
| Q4 25 | $35.1M | $137.0M | ||
| Q3 25 | $2.4M | $124.8M | ||
| Q2 25 | $22.4M | $121.1M | ||
| Q1 25 | $12.2M | $101.3M | ||
| Q4 24 | $-31.1M | $117.9M | ||
| Q3 24 | $-156.0K | $111.2M | ||
| Q2 24 | $6.0M | $99.5M | ||
| Q1 24 | $-91.6M | $76.5M |
| Q4 25 | 36.5% | 37.5% | ||
| Q3 25 | 34.9% | 37.7% | ||
| Q2 25 | 39.5% | 37.2% | ||
| Q1 25 | 36.8% | 36.3% | ||
| Q4 24 | 36.0% | 38.5% | ||
| Q3 24 | 38.4% | 37.3% | ||
| Q2 24 | 35.6% | 36.2% | ||
| Q1 24 | 36.1% | 35.6% |
| Q4 25 | 13.8% | 19.2% | ||
| Q3 25 | 9.0% | 19.1% | ||
| Q2 25 | 15.4% | 17.8% | ||
| Q1 25 | 14.4% | 16.0% | ||
| Q4 24 | 10.4% | 18.8% | ||
| Q3 24 | 12.6% | 18.1% | ||
| Q2 24 | 13.6% | 16.4% | ||
| Q1 24 | -1.6% | 14.0% |
| Q4 25 | 4.3% | 14.5% | ||
| Q3 25 | 0.3% | 14.4% | ||
| Q2 25 | 3.1% | 13.8% | ||
| Q1 25 | 1.8% | 12.6% | ||
| Q4 24 | -4.3% | 14.3% | ||
| Q3 24 | -0.0% | 13.9% | ||
| Q2 24 | 0.9% | 12.7% | ||
| Q1 24 | -13.9% | 10.7% |
| Q4 25 | $0.10 | $3.69 | ||
| Q3 25 | $0.01 | $3.31 | ||
| Q2 25 | $0.07 | $3.19 | ||
| Q1 25 | $0.04 | $2.68 | ||
| Q4 24 | $-0.10 | $3.09 | ||
| Q3 24 | $0.00 | $2.89 | ||
| Q2 24 | $0.02 | $2.58 | ||
| Q1 24 | $-0.30 | $1.99 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.0M | — |
| Total DebtLower is stronger | $2.6B | $957.9M |
| Stockholders' EquityBook value | $-70.8M | $2.5B |
| Total Assets | $3.7B | $5.2B |
| Debt / EquityLower = less leverage | — | 0.38× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.0M | — | ||
| Q3 25 | $201.2M | — | ||
| Q2 25 | $71.5M | — | ||
| Q1 25 | $59.2M | $226.5M | ||
| Q4 24 | $110.6M | $385.0M | ||
| Q3 24 | $74.0M | — | ||
| Q2 24 | $43.8M | — | ||
| Q1 24 | $46.5M | $338.0M |
| Q4 25 | $2.6B | $957.9M | ||
| Q3 25 | $2.6B | $968.6M | ||
| Q2 25 | $2.2B | $958.4M | ||
| Q1 25 | $2.2B | $958.6M | ||
| Q4 24 | $2.4B | $1.0B | ||
| Q3 24 | $2.4B | $1.0B | ||
| Q2 24 | $2.4B | $1.0B | ||
| Q1 24 | $2.4B | $1.1B |
| Q4 25 | $-70.8M | $2.5B | ||
| Q3 25 | $-109.5M | $2.5B | ||
| Q2 25 | $-112.1M | $2.7B | ||
| Q1 25 | $-131.7M | $2.6B | ||
| Q4 24 | $-109.3M | $2.4B | ||
| Q3 24 | $-93.4M | $2.5B | ||
| Q2 24 | $-57.5M | $2.5B | ||
| Q1 24 | $-63.7M | $2.4B |
| Q4 25 | $3.7B | $5.2B | ||
| Q3 25 | $3.6B | $5.1B | ||
| Q2 25 | $3.4B | $5.2B | ||
| Q1 25 | $3.4B | $5.0B | ||
| Q4 24 | $3.5B | $5.0B | ||
| Q3 24 | $3.5B | $4.9B | ||
| Q2 24 | $3.5B | $4.7B | ||
| Q1 24 | $3.5B | $4.6B |
| Q4 25 | — | 0.38× | ||
| Q3 25 | — | 0.38× | ||
| Q2 25 | — | 0.35× | ||
| Q1 25 | — | 0.37× | ||
| Q4 24 | — | 0.43× | ||
| Q3 24 | — | 0.42× | ||
| Q2 24 | — | 0.43× | ||
| Q1 24 | — | 0.44× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $130.3M | $352.7M |
| Free Cash FlowOCF − Capex | $108.5M | $315.1M |
| FCF MarginFCF / Revenue | 13.3% | 33.3% |
| Capex IntensityCapex / Revenue | 2.7% | 4.0% |
| Cash ConversionOCF / Net Profit | 3.72× | 2.57× |
| TTM Free Cash FlowTrailing 4 quarters | $269.9M | $553.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $130.3M | $352.7M | ||
| Q3 25 | $118.5M | $192.8M | ||
| Q2 25 | $83.8M | $136.6M | ||
| Q1 25 | $7.4M | $-38.8M | ||
| Q4 24 | $118.1M | $301.3M | ||
| Q3 24 | $141.8M | $177.3M | ||
| Q2 24 | $39.7M | $111.3M | ||
| Q1 24 | $-4.4M | $-45.6M |
| Q4 25 | $108.5M | $315.1M | ||
| Q3 25 | $106.2M | $175.9M | ||
| Q2 25 | $61.0M | $117.2M | ||
| Q1 25 | $-5.8M | $-54.5M | ||
| Q4 24 | $102.9M | $278.0M | ||
| Q3 24 | $124.8M | $162.7M | ||
| Q2 24 | $29.0M | $100.3M | ||
| Q1 24 | $-13.6M | $-57.7M |
| Q4 25 | 13.3% | 33.3% | ||
| Q3 25 | 13.5% | 20.2% | ||
| Q2 25 | 8.4% | 13.4% | ||
| Q1 25 | -0.8% | -6.8% | ||
| Q4 24 | 14.1% | 33.7% | ||
| Q3 24 | 17.8% | 20.4% | ||
| Q2 24 | 4.1% | 12.8% | ||
| Q1 24 | -2.1% | -8.1% |
| Q4 25 | 2.7% | 4.0% | ||
| Q3 25 | 1.6% | 1.9% | ||
| Q2 25 | 3.2% | 2.2% | ||
| Q1 25 | 1.9% | 2.0% | ||
| Q4 24 | 2.1% | 2.8% | ||
| Q3 24 | 2.4% | 1.8% | ||
| Q2 24 | 1.5% | 1.4% | ||
| Q1 24 | 1.4% | 1.7% |
| Q4 25 | 3.72× | 2.57× | ||
| Q3 25 | 50.00× | 1.54× | ||
| Q2 25 | 3.74× | 1.13× | ||
| Q1 25 | 0.61× | -0.38× | ||
| Q4 24 | — | 2.56× | ||
| Q3 24 | — | 1.59× | ||
| Q2 24 | 6.62× | 1.12× | ||
| Q1 24 | — | -0.60× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMRX
| Oral Solid | $188.7M | 23% |
| Distribution Service | $107.7M | 13% |
| Central Nervous System | $104.8M | 13% |
| Government Label | $86.8M | 11% |
| Other Dosage Forms | $68.2M | 8% |
| Transdermal | $56.1M | 7% |
| Hormonal Allergy | $47.6M | 6% |
| Ephinephrine Auto Injector | $39.1M | 5% |
| Injectable | $37.4M | 5% |
| Other | $33.6M | 4% |
| Biosimilar | $29.4M | 4% |
| Selling General And Administrative Expenses | $14.9M | 2% |
CW
| Naval Power | $417.4M | 44% |
| Defense Electronics | $268.3M | 28% |
| Aerospace Industrial | $262.4M | 28% |
